Metsera, Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Metsera, Inc. 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MTSR

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. 

CEO
Christopher Whitten Bernard
CEOChristopher Whitten Bernard
Employees
81
Employees81
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2022
Founded2022
Employees
81
Employees81

MTSR Key Statistics

Market cap
3.51B
Market cap3.51B
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
1.62M
Average volume1.62M
High today
$34.60
High today$34.60
Low today
$32.26
Low today$32.26
Open price
$33.99
Open price$33.99
Volume
2.38M
Volume2.38M
52 Week high
$47.40
52 Week high$47.40
52 Week low
$12.30
52 Week low$12.30

People also own

Based on the portfolios of people who own MTSR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.